Industry & Business

BioMarin expands facility to manufacture medicine for rare genetic diseases

 Breaking News
  • Largest Ever European Investment Bank Support in Ireland The European Investment Bank is to provide a loan of €490 million to support construction of the new children’s hospital in Dublin. This represents the largest ever financial engagement by the European Union’s long-term lending institution in Ireland and the EIB’s first backing for a hospital in the country. The new children’s hospital project includes two [...]...
  • Strabane Manufacturer to Invest Over £7 Million in Ambitious Expansion Strabane-based Fabplus is planning to more than double its workforce and turnover with support from Invest Northern Ireland. The investment is part of a three year expansion plan to increase its market share in the Republic of Ireland and Great Britain, and gain a foothold in mainland Europe and Scandinavia. Recruitment is underway to employ 83 additional staff at [...]...
  • PM Group Appoints a New Non-Executive Director Michael McNicholas has been appointed as a Non-Executive Director of Project Management Holdings (PM Group), the Irish headquartered international project delivery specialists. Michael McNicholas. Michael has over 35 years’ experience in senior leadership positions in the public and private sectors. He is the former CEO of Ervia, NTR plc and Managing Director of ESB International.  During his [...]...
  • Center Parcs Signs Contract With John Sisk & Son As construction activity on the much anticipated €233 million Center Parcs Longford Forest resort in County Longford ramps up, the company has announced it has formally awarded two major construction contracts to Dublin-based construction firm John Sisk & Son. The contracts for the construction of the 470 lodges and 30 apartments as well as the state-of-the-art centre [...]...
  • Medi-Shower Invests in Innovation to Drive Export Growth Multi-award-winning manufacturer Medi-Shower has created ‘smart showerhead’ technology which can reduce the risk of Legionnaires disease. The cutting edge product, developed with R&D support from Invest Northern Ireland is designed to meet the high requirements for hygiene within the healthcare sector. It reduces the risk of waterborne infection from bacteria that can build up due to poor design [...]...

BioMarin expands facility to manufacture medicine for rare genetic diseases

BioMarin expands facility to manufacture medicine for rare genetic diseases
July 31
09:00 2017

Simon Coveney, Minister for Foreign Affairs and Trade, has officially opened a new expansion at BioMarin Pharmaceutical Inc. in Shanbally, Co Cork. BioMarin has recently extended its site footprint to 20 acres as the company continues to experience a rise in the global demand for its therapies to treat rare genetic diseases that mostly affect children.

Since opening its doors in 2011, the company has grown to 365 employees in Cork, with an additional 67 people based in Dublin and 2,400 employees globally. BioMarin focuses on developing first-­‐in-­class and best-­in-­class therapeutics that have the potential to improve clinical outcomes of patients with rare genetic diseases. The company currently has six approved products that are the only drugs available on the market today for the diseases they treat.

This expansion project began two years ago to cater for continued growth at the site and includes an expanded warehouse, new administration and utilities offices, a canteen and conference facilities. The overall project will allow the company to maximise the flexibility of the site with the expansion of the operational manufacturing capacity. The site will also see the installation of a Waste Water Treatment Plant later this year, while three new lab expansions are to be completed by Q3 2018.

Jean-­Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin stated: “Ireland has proved to be an ideal location to expand our operations. The team at Shanbally has enabled us to accommodate our growing commercial portfolio and advancing clinical programs. Mostly children, our patients suffer from diseases so rare that the entire afflicted population may number as few as 1,000 worldwide. Often inherited, difficult to diagnose, and progressively debilitating, these conditions have, up until now, been largely ignored. As we continue to grow in Shanbally, we are looking to recruit the best and brightest in a variety of disciplines to help us continue our inspiring work for patients.”

Welcoming the expansion, Simon Coveney said: “Today’s announcement represents a significant investment in the local economy. Shanbally is BioMarin’s only manufacturing facility outside the US and what they have done in such a few short years is very impressive. The company is continuing to grow and I understand that there are up to 50 open positions across a variety of departments at Shanbally waiting to be filled. BioMarin is a prime example of the high-­‐tech Life Sciences companies that this area of Cork has a reputation for.”

CEO of IDA Ireland Martin Shanahan said: “I am delighted that BioMarin continues to consolidate its commitment to its Irish operations in Shanbally. The company’s presence in Cork strengthens Ireland’s global reputation as a biopharmaceutical industry leader and brings high quality jobs to countless people across the south-­west region. We look forward to working closely with the company as it further develops its operations here.”

About Author

editor

editor

Related Articles






New Subscriber





Subscribe Here



Advertisements
































National Manufacturing Conference & Exhibition 2016

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4